Dabrafenib and Trametinib Show Promise in Advanced Cholangiocarcinoma
Phase 2 clinical trial shows promising result for dabrafenib and trametinib combination in patients with advanced cholangiocarcinoma with a BRAFV600E mutation.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
First-Line Nivolumab Plus Chemotherapy Improves Survival in Gastric, Gastroesophageal Junction, and Esophageal Cancers
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
Pembrolizumab Plus Chemotherapy Prolonged Survival in Esophageal or EGJ Cancers
First-line pembrolizumab plus chemotherapy prolonged survival among patients with advanced esophageal or esophagogastric junction cancer.
Genomic Instability Predicts Risk of Progression for Barrett Esophagus
Genomic copy number instability predicted the risk of disease progression among patients with Barrett esophagus years beforehand.
Geriatric Nutritional Risk Index Predictive of Outcomes Following Colorectal Cancer Surgery
A retrospective study sought to determine the accuracy of the GNRI in predicting postoperative complications and overall survival in elderly patients with colorectal cancer.
Improved Outcomes With Cabozantinib in HCC Across All Baseline AFP Levels
Cabozantinib prolonged survival compared with placebo regardless of baseline AFP levels. Lower baseline AFP levels associated with the longest survival.
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
Analysis of Ramucirumab Suggests Risks Outweigh Benefits
A meta-analysis of randomized controlled trials found that there are significant risks for severe or fatal adverse events with ramucirumab, with only modest improvements in OS or PFS.
Conflicts of Interest Continue to Plague Oncology Guidelines and Research
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
FDA Denies Accelerated Approval of Keytruda Plus Lenvima for Unresectable HCC
In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.
Keytruda Approved as First-Line Treatment of MSI-H or dMMR Colorectal Cancer
The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Antidiabetic Medication Adherence, Survival for Patients With Diabetes and Colorectal Cancer
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
Opdivo Approved for Advanced Esophageal Squamous Cell Carcinoma
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
Comparing Stereotactic Body Radiation Therapy With Transarterial Chemoembolization in Early-Stage HCC
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
Lenvatinib, Pembrolizumab Combination Promising in Unresectable HCC
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gastrointestinal Cancers News
